Operational Costs Compared: SG&A Analysis of Incyte Corporation and Sarepta Therapeutics, Inc.

A Decade of SG&A: Incyte vs. Sarepta

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Incyte Corporation and Sarepta Therapeutics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Incyte's SG&A expenses surged by approximately 600%, reflecting its aggressive expansion and strategic investments. In contrast, Sarepta's expenses grew by nearly 900%, indicating its rapid scaling and market penetration efforts.

Key Insights

• Incyte's Growth: By 2023, Incyte's SG&A expenses reached over 1.16 billion, a testament to its robust operational strategies.
• Sarepta's Expansion: Sarepta's expenses, while lower in absolute terms, showed a significant upward trend, peaking at nearly 482 million in 2023.
  This analysis underscores the dynamic nature of biotech firms' operational strategies, offering a glimpse into their financial priorities and market positioning.